Skip to content

Evaluation of Transdermal Nicotine Replacement Therapy (NRT) Activity Through Metabolic Induction

Evaluation of Nicotine Receptor Up-regulation Activity Through Metabolic Induction and Changes in Responsiveness Using Surrogate Evaluation Methods

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01438944
Enrollment
52
Registered
2011-09-22
Start date
2011-07-31
Completion date
2015-09-30
Last updated
2017-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addiction, Smoking

Keywords

NRT, Patch, smoking, addiction

Brief summary

Evaluation to determine if auto-induction can be used as a surrogate measure of nicotine receptor up-regulation through an observational study using nicotine replacement therapy for two weeks and no intervention for two weeks.

Detailed description

Studies have shown that prolonged exposure to nicotine reinforces addiction. The act of smoking delivers nicotine through lungs into the blood stream. As a result, during smoking nicotine levels peak and then when smoking stops levels progressively diminish to a base (trough) level. At the peak level a smoker feels rewarded, but at the trough level a smoker starts to experience negative withdrawal affects and a desire to smoke. Nicotine Gum and Inhalers mimic this smoking behaviour maintaining a peak and trough regime, but nicotine patches do not. Instead, nicotine patches deliver a constant base dose considered to be either above that of the smokers trough level or at a level where negative withdrawal effects are reduced. The question arises as to if nicotine levels delivered by a patch are constant and potentially above that of the baseline smokers level, does this reinforce the addiction and therefore contribute to the high long term relapse rate? To answer this question the investigators will be looking at metabolites which the body uses to breakdown nicotine and several other enzymes. These metabolites respond to the levels of nicotine in the blood stream by increasing or decreasing over time. By testing blood flow, blood and urine the investigators are able to gain an insight into how the body is dealing with a constant stable dose of nicotine rather than a peak and trough dose. In combination with the questionnaires the investigators will be able to determine the level of affect.

Interventions

DRUGNicabate 21mg transdermal NRT

Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.

Sponsors

Basil Hetzel Institute for Translational Research
CollaboratorUNKNOWN
University of Adelaide
CollaboratorOTHER
University of South Australia
CollaboratorOTHER
Clinical Practice Unit
CollaboratorUNKNOWN
Therapeutics Research Centre
CollaboratorUNKNOWN
The Queen Elizabeth Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Smokers who currently smoke at least 10 cigarettes per day * Aged between 18 and 75 * Informed consent * Willingness to attempt to quit smoking for the period specified, initially with a transdermal patch for 14 days and then without any smoking cessation aids for a further 14 days.

Exclusion criteria

* Use of bupropion, champix or nicotine containing products other than cigarettes in the last 2 months * previous reactions to NRT * Pregnancy / Breast Feeding * Uncontrolled hypertension * Unstable angina * Heart attack or stroke within the previous 6 months * Severe Obesity as indicated by Body Mass Index (BMI) ≥35 (potential for slow release of nicotine from tissues) * acute psychiatric illness, past history psychosis, suicidal ideation or current diminished capacity. * Current treatment or recent diagnosis of cancer * Current use of Phenobarbital or other anticonvulsant drugs (induction of metabolism of nicotine to cotinine) * Renal failure (creatinine clearance\<30ml/min - reduces metabolic clearance of cotinine and nicotine)

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline Nicotine, cotinine, Leptin and orexin Metabolite ratiosBaseline, Day 4, Day 14 and Day 28Baseline Prior to Transdermal NRT patch application Day 4 NRT Patch Application Day 14 Last Day NRT Patch Application Day 28 14 Days post NRT patch removal.

Secondary

MeasureTime frameDescription
Change from baseline Patient Instruments: Fagerstrom Test for Nicotine Dependence (FTND), Wisconsin Smoking Withdrawal Scale (WSWS), Michigan Nicotine Reinforcement Questionnaire (MNRQ), Smoker DiaryBaseline, Day 14 and Day 28Comparative evaluation patient instruments with ratios of metabolite induction

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026